Gonzales R D, Schreckenberger P C, Graham M B, Kelkar S, DenBesten K, Quinn J P
Lancet. 2001 Apr 14;357(9263):1179. doi: 10.1016/S0140-6736(00)04376-2.
Linezolid is a new oxazolidinone antibiotic used to treat infections caused by vancomycin-resistant enterococci (VRE). In early clinical trials, emergence of resistance occurred rarely. We report clinical details and antibiotic susceptibility from five patients treated with linezolid for VRE infections who had resistant organisms isolated during therapy. Four were transplant patients receiving protracted courses of the drug; three cases were associated with treatment failure. One of 45 linezolid-treated patients developed resistance during therapy. Susceptibility testing should be done in all cases on starting therapy.
利奈唑胺是一种新型恶唑烷酮类抗生素,用于治疗由耐万古霉素肠球菌(VRE)引起的感染。在早期临床试验中,耐药情况很少出现。我们报告了5例接受利奈唑胺治疗VRE感染患者的临床细节和抗生素敏感性,这些患者在治疗期间分离出了耐药菌。其中4例是接受长期药物治疗的移植患者;3例与治疗失败有关。45例接受利奈唑胺治疗的患者中有1例在治疗期间出现耐药。所有病例在开始治疗时均应进行药敏试验。